Navigation Links
Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol, Can Help to Improve Cardiovascular Health
Date:6/24/2009

Study Published in Annals of Internal Medicine

CHERRY HILL, N.J., June 24 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company, announced today that red yeast rice, an ingredient contained in Cinnechol, one of the Company's primary supplement products, has been recently proven to decrease levels of low-density lipoprotein, or LDL cholesterol, in dyslipidemic patients. LDL cholesterol is known more informally as "bad" cholesterol. Red yeast rice, which has been used in Ayurvedic medicine and China as a dietary supplement for centuries, contains a compound (monacolin K) that is identical in chemical composition to lovastatin, a commonly prescribed cholesterol-lowering drug.

A recent study titled "Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial," led by cardiologists Dr. David Becker and Dr. Ram Gordon and published in the Annals of Internal Medicine, showed that a diet and exercise regimen that included red yeast rice reduced LDL cholesterol by an average of 27.3%, compared to 5.7% for the control group. Moreover, the study showed that red yeast rice can decrease LDL cholesterol without increasing pain levels.

"Many synthetic statins have been derived from red yeast rice and other naturally occurring phytochemicals," stated Robert Bowker, co-inventor of Cinnechol and President of Knock-Out Technologies, Ltd., a wholly owned subsidiary of Nuvilex. "Red yeast rice, among others, is a bona fide naturally occurring statin. Cinnechol--along with diet and exercise--can help individuals maintain normal cholesterol levels and promote cardiovascular health."

Cinnechol, which contains red yeast rice extract as well as a blend of other ingredients known to improve cardiovascular function (including niacin and guggul gum extract), may provide a natural alternative for those who have high cholesterol and are intolerant of, or elect not to take, statin drugs. Cinnechol can be purchased online by visiting www.cinnechol.com.

"Red yeast rice has now been more thoroughly researched and recognized as an important tool for safely normalizing blood lipids, especially LDL cholesterol," reported Cinnechol co-inventor Steven Kushner, Ph.D. "Cinnechol, by combining Red Yeast Rice with several cardiovascular beneficial synergists, also helps promote healthy total cholesterol levels, improved HDL (beneficial cholesterol) levels, and better blood viscosity."

About Cinnechol

Cinnechol, an ingestible capsule made of all-natural ingredients, is manufactured and sold by Cinnechol, Inc. (a wholly owned subsidiary of Nuvilex, Inc.). Cinnechol is designed to help maintain normal cholesterol levels and to support normal cardiovascular function. Cinnechol, along with a healthy diet and exercise regimen, is intended to serve as a dietary supplement to help individuals manage numerous cardiovascular and metabolic disorders (including dyslipidemia, hypertension, hypoglycemia, and hyperglycemia).

About Nuvilex, Inc.

Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Amy Glynn/Ashleigh Barreto
    The Ruth Group
    Ph: 646-536-7023/7028
    Email: aglynn@theruthgroup.com
    Email: abarreto@theruthgroup.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream
2. Nuvilex Featured in Wall Street Reporter Interview
3. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
4. Nuvilex Launches Video Marketing Campaign
5. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
6. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
7. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
8. Nuvilex, Inc. Announces Monthly Investor Conference Call
9. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
10. Nuvilex, Inc. Announces Investor Conference Call and Open House
11. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology: